Opinion|Videos|October 7, 2024
Latest Advances and Therapies for HER2+ NSCLC
Key Takeaways
- Emerging HER2-directed therapies show promise in NSCLC, with significant results from SOHO-01, inetetamab/pyrotinib, and Beamion LUNG-1 studies.
- These studies indicate a potential shift in the treatment landscape, offering new options for patients with HER2 mutations in NSCLC.
Panelists discuss how recent clinical trial results for emerging HER2-directed therapies, including findings from the SOHO-01 study, inetetamab/pyrotinib combination study, and Beamion LUNG-1, are shaping the future landscape of NSCLC treatment, while also highlighting other noteworthy developments presented at this year’s World Conference on Lung Cancer.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Several HER2-directed therapies are currently in development. Could you discuss the recent clinical trial results for emerging agents, such as those from the SOHO-01 study, the inetetamab/pyrotinibcombination study, and the Beamion LUNG-1 study, and what implications these findings might have for the future landscape of HER2-directed therapies in NSCLC?
- (Heymach) What other notable data from this year’s World Conference on Lung Cancer are you most excited about?
Advertisement
Related to this article
A systematic review and meta-analysis found GLP-1 RAs improved liver and metabolic markers in MASLD and MASH, but long-term benefits remain unproven.
Mailed fecal immunochemical test (FIT) outreach raised CRC screening at federally qualified health centers, but gains faded by year 3.
SIRVA was rare after COVID-19 and flu shots, but COVID-19 vaccination had about 7 more cases per 100,000 doses in a study of 1.8 million.
Mucus plugs on chest CT may signal higher COPD hospitalization and death risk even without cough, and early data suggest they can be treated.
Antimicrobial resistance in bronchiectasis and cystic fibrosis varied widely in a study spanning 11 centers on 3 continents.
Experts break down the GOLD 2026 COPD guidelines, highlighting updates to diagnosis criteria, Group E risk categories, and nonpharmacologic interventions.
An economic evaluation found nontargeted hepatitis C screening in emergency departments offered the greatest health benefit at a cost-effective price.
Advertisement
Advertisement
Trending on AJMC
1
Hepatitis B Functional Cure Persists Off Treatment After Bepirovirsen
2
Health Equity & Access Weekly Roundup: November 6, 2026
3
Medicaid Cuts and Caregiving in Congress: Andy Kim
4
COPD’s Old Narrative Is Outdated, GOLD Leaders Say in 2027 Update
5